Cargando…

Tocilizumab for the Treatment of Familial Mediterranean Fever—A Randomized, Double-Blind, Placebo-Controlled Phase II Study

Background: The purpose of this trial was to evaluate the effectiveness and safety of the IL-6 receptor antibody Tocilizumab (TCZ) in the treatment of Familial Mediterranean Fever (FMF). Methods: This was a randomized, double-blinded, placebo-controlled phase II trial in adult patients with active F...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henes, Joerg C., Saur, Sebastian, Kofler, David M., Kedor, Claudia, Meisner, Christoph, Schuett, Marion, Krusche, Martin, Koetter, Ina, Xenitidis, Theodoros, Schulze-Koops, Hendrik, Feist, Eugen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500594/ https://www.ncbi.nlm.nih.gov/pubmed/36143006 http://dx.doi.org/10.3390/jcm11185360

Ejemplares similares

Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
por: Kedor, Claudia, et al.
Publicado: (2020)

Sexual dysfunction and depression in Behçet’s disease in comparison to healthy controls
por: Saur, Sebastian-Jonas, et al.
Publicado: (2021)

Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review
por: Kedor, Claudia, et al.
Publicado: (2021)

Tumefactive demyelinating CNS lesion in a 60-year-old woman with familial Mediterranean fever
por: Trostel, Constanze, et al.
Publicado: (2021)

Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever
por: Ugurlu, Serdal, et al.
Publicado: (2017)

Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
por: Butryn, Michaela, et al.
Publicado: (2021)

A prospective pilot study to evaluate an animated home-based physical exercise program as a treatment option for patients with rheumatoid arthritis
por: Zernicke, Jan, et al.
Publicado: (2016)

Unauthorized change of immunosuppressants by patients with rheumatic diseases in the COVID-19 pandemic: a cross-sectional analysis of a patient survey
por: Dahm, Simon, et al.
Publicado: (2023)

Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still’s Disease and Active Articular Manifestation Responding to Canakinumab
por: Ghannam, Khetam, et al.
Publicado: (2021)

Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series
por: Tzaribachev, Nikolay, et al.
Publicado: (2009)

Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial
por: Koga, Tomohiro, et al.
Publicado: (2018)

Lymphopenia and autoimmune diseases
por: Schulze-Koops, Hendrik
Publicado: (2004)

Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases
por: Schulze-Koops, Hendrik
Publicado: (2017)

Zytokin profiles in familial Mediterranean fever patients: IL-18 as a major cytokine and potential biomarker or target
por: Igney-Oertel, A, et al.
Publicado: (2015)

Response to abatacept is associated with the inhibition of proteasome β1i expression in T cells of patients with rheumatoid arthritis
por: Ghannam, Khetam, et al.
Publicado: (2020)

Autoinflammatorische Syndrome
por: Bonnekoh, Hanna, et al.
Publicado: (2023)

Clinical and Histopathological Features of Patients with Systemic Sclerosis Undergoing Endomyocardial Biopsy
por: Mueller, Karin A. L., et al.
Publicado: (2015)

Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria
por: Iking-Konert, Christof, et al.
Publicado: (2011)

Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab
por: Stone, John H., et al.
Publicado: (2019)

The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells
por: Dodeller, Francis, et al.
Publicado: (2006)

IgG4-related sialadenitis: IgG4 is helpful, but biopsies are still crucial
por: Witte, Torsten, et al.
Publicado: (2015)

Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm
por: Schulze-Koops, Hendrik, et al.
Publicado: (2017)

COVID-19 vaccination in individuals with inflammatory rheumatic diseases
por: Skapenko, Alla, et al.
Publicado: (2022)

Management of a patient with common variable immunodeficiency and hepatopathy
por: Grümme, Lea, et al.
Publicado: (2023)

Atypical Familial Mediterranean Fever Complicated with Gastrointestinal Amyloidosis Diagnosed due to Paroxysmal Arthralgia and Intractable Diarrhea, Successfully Treated with Tocilizumab
por: Aikawa, Erika, et al.
Publicado: (2019)

1.5 Decades Later: Bearing fruits from the ACR/EULAR exchange Program
por: Cron, Randy Q, et al.
Publicado: (2011)

Where is biological therapy going?
por: Schulze-Koops, Hendrik, et al.
Publicado: (2000)

22nd European Workshop for Rheumatology Research, Leiden, The Netherlands, 28 February–3 March 2002
por: Cope, Andrew P, et al.
Publicado: (2002)

Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany
por: Tony, Hans-Peter, et al.
Publicado: (2022)

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease
por: Gabay, Cem, et al.
Publicado: (2018)

The Role of Antiphospholipid Antibodies in COVID-19
por: Stelzer, Maximilian, et al.
Publicado: (2021)

Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines
por: Schulze-Koops, Hendrik, et al.
Publicado: (2021)

Reactive arthritis after SARS-CoV-2 infection
por: Dombret, Sophia, et al.
Publicado: (2022)

Digital Health Transition in Rheumatology: A Qualitative Study
por: Mühlensiepen, Felix, et al.
Publicado: (2021)

Successful treatment with the IL12/IL23 antagonist ustekinumab in a patient with refractory Takayasu arteritis
por: Saur, Sebastian-Jonas, et al.
Publicado: (2021)

Cholestatic Liver Disease after Rituximab and Adalimumab and the Possible Role of Cross-Reacting Antibodies to Fab 2 Fragments
por: Latus, Joerg, et al.
Publicado: (2013)

Tocilizumab in severe COVID-19 – A randomized, double-blind, placebo-controlled trial
por: Malik, Muhammad Irfan, et al.
Publicado: (2022)

Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure
por: Kekow, Joern, et al.
Publicado: (2012)

Obstacles to Anti-CD4 Therapy in Rheumatoid Arthritis
por: Kalden, Joachim R, et al.
Publicado: (2000)

After 25 years of drug development, do we know JAK?
por: Mortezavi, Mahta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gm4o764vckvvb6n9p8tif8ggls